for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novo Nordisk A/S

NOVOb.CO

Latest Trade

427.10DKK

Change

10.10(+2.42%)

Volume

2,665,925

Today's Range

413.10

 - 

427.10

52 Week Range

328.70

 - 

456.30

As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Novo Nordisk in Q2 spent 1 bln DKK less than normally expected

Aug 6 (Reuters) - Novo Nordisk A/S <NOVOb.CO>::CEO SAYS ALL NOVO NORDISK MANUFACTURING SITES ARE OPERATING AND PRODUCTS ARE BEING DISTRIBUTED.CEO SAYS RECRUITING NEW PATIENTS FOR ONGOING TRIALS IS NEGATIVELY IMPACTED BUT IMPROVING, INITIATING NEW TRIALS IN SOME COUNTRIES POSSIBLE.CEO SAYS OPERATIONS GRADUALLY NORMALISING IN MANY MARKETS, MAJORITY OF SALES REPRESENTATIVES NOW PARTIALLY BACK IN FIELD.CFO SAYS SPENDING WAS ABOUT 1 BILLION DKK LOWER THAN NORMALLY EXPECTED FOR THE SECOND QUARTER.

Novo Nordisk H1 Oper Profit Up At DKK 30,140 Mln

Aug 6 (Reuters) - Novo Nordisk A/S <NOVOb.CO>::FOR 2020 OUTLOOK, SALES GROWTH IS STILL EXPECTED TO BE 3-6% AT CER, AND OPERATING PROFIT GROWTH IS NOW EXPECTED TO BE 2-5% AT CER.NOVO NORDISK H1 NET SALES DKK 63,881 MILLION VERSUS DKK 59,327 MILLION YEAR AGO.NOVO NORDISK H1 OPERATING PROFIT DKK 30,140 MILLION VERSUS DKK 27,691 MILLION YEAR AGO.Q2 REVENUE DKK 30,006 MILLION VERSUS DKK 30,742 MILLION SEEN IN REFINITIV POLL.Q2 OPERATING PROFIT DKK 13,838 MILLION VERSUS DKK 13,308 MILLION SEEN IN REFINITIV POLL.NOVO NORDISK H1 SALES OF OZEMPIC AT DKK 9,591 MILLION.NOVO NORDISK H1 SALES OF VICTOZA AT DKK 9,225 MILLION.NOVO NORDISK EXPECTS 2020 FREE CASH FLOW OF DKK 33-38 BILLION VERSUS PREVIOUSLY SEEN DKK 36-41 BILLION.NOVO NORDISK EXPECTS 2020 OPERATING GROWTH OF 2-5% VERSUS PREVIOUSLY SEEN 1-5%.EXPECTS 2020 FINANCIAL ITEMS (NET) LOSS OF AROUND DKK 1.2 BILLION VERSUS LOSS OF AROUND DKK 2.5 BILLION PREVIOUSLY SEEN.SALES OF GLP-1 PRODUCTS FOR TYPE 2 DIABETES (VICTOZA, OZEMPIC AND RYBELSUS) INCREASED BY 30% MEASURED IN DANISH KRONER AND BY 28% AT CER TO DKK 19,400 MILLION.

Novo Nordisk: Rybelsus Approved In Japan

June 29 (Reuters) - Novo Nordisk A/S <NOVOb.CO>::REG-RYBELSUS® APPROVED IN JAPAN FOR THE TREATMENT OF TYPE 2 DIABETES.JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE HAS APPROVED RYBELSUS(®) (ORAL SEMAGLUTIDE).WILL NOW INITIATE REIMBURSEMENT NEGOTIATIONS AND EXPECTS TO LAUNCH RYBELSUS(®) IN JAPAN THEREAFTER.JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE HAS APPROVED RYBELSUS(®) (ORAL SEMAGLUTIDE) FOR TREATMENT OF ADULTS WITH TYPE 2 DIABETES..

Novo Nordisk Successfully Completes Am833 Phase 2 Trial And Phase 1 Combination Trial

June 18 (Reuters) - Novo Nordisk A/S <NOVOb.CO>::REG-NOVO NORDISK SUCCESSFULLY COMPLETES AM833 PHASE 2 TRIAL AND PHASE 1 COMBINATION TRIAL WITH AM833 AND SEMAGLUTIDE IN OBESITY.NOVO NORDISK - NOVO NORDISK TODAY ANNOUNCED HEADLINE RESULTS FROM TWO CLINICAL TRIALS.NOVO NORDISK - PHASE 1 AND 2 DATA WITH AM833 FOR WEIGHT MANAGEMENT, ESPECIALLY COMBINATION WITH SEMAGLUTIDE, FURTHER STRENGTHEN NOVO NORDISK'S OBESITY PIPELINE AND HOLD POTENTIAL TO CLOSE GAP BETWEEN PHARMACOTHERAPY AND BARIATRIC SURGERY.NOVO NORDISK - THE TRIAL REACHED ITS PRIMARY ENDPOINT BY DEMONSTRATING A WEIGHT LOSS OF 10.8% AT WEEK 26 WITH AM833 AT THE 4.5 MG DOSE, COMPARED TO A WEIGHT LOSS OF 3.0 % WITH PLACEBO. THE TREATMENT DIFFERENCE WAS STATISTICALLY SIGNIFICANT.

Novo Nordisk: Semaglutide 2.4 Mg Shows Superior Weight Loss Versus Placebo In Phase 3 Trials

June 12 (Reuters) - Novo Nordisk A/S <NOVOb.CO>::REG-SEMAGLUTIDE 2.4 MG SHOWS SUPERIOR WEIGHT LOSS VERSUS PLACEBO IN THE PHASE 3 TRIALS STEP 2 AND STEP 3, THEREBY SUCCESSFULLY COMPLETING THE PROGRAMME.ANNOUNCED HEADLINE RESULTS FROM FINAL TWO PHASE 3A CLINICAL TRIALS INVESTIGATING ONCE-WEEKLY SUBCUTANEOUS (SC) SEMAGLUTIDE 2.4 MG FOR WEIGHT MANAGEMENT.TRIAL MET BOTH PRIMARY ENDPOINTS.IN BOTH STEP 2 AND STEP 3, SC SEMAGLUTIDE 2.4 MG APPEARED TO HAVE A SAFE AND WELL‑TOLERATED PROFILE, CONSISTENT WITH PREVIOUS FINDINGS.MOST COMMON ADVERSE EVENTS AMONG PEOPLE TREATED WITH SC SEMAGLUTIDE 2.4 MG WERE GASTROINTESTINAL EVENTS.

HBM Healthcare Investments: Novo Nordisk Buys Portfolio Company

June 11 (Reuters) - HBM HEALTHCARE INVESTMENTS AG <HBMN.S>::NOVO NORDISK ACQUIRES HBM PORTFOLIO COMPANY CORVIDIA THERAPEUTICS FOR UP TO USD 2.1 BILLION IN CASH.

Novo Nordisk To Acquire Corvidia Therapeutics

June 11 (Reuters) - Novo Nordisk A/S <NOVOb.CO>::NOVO NORDISK TO ACQUIRE CORVIDIA THERAPEUTICS AND EXPAND PRESENCE IN CARDIOVASCULAR DISEASE.UNDER TERMS OF AGREEMENT, NOVO NORDISK WILL ACQUIRE ALL OUTSTANDING SHARES OF CORVIDIA THERAPEUTICS FOR AN UPFRONT PAYMENT OF 725 MILLION US DOLLARS IN CASH.TRANSACTION WILL NOT IMPACT NOVO NORDISK'S PREVIOUSLY COMMUNICATED OPERATING PROFIT OUTLOOK FOR 2020.TOTAL PAYMENTS TO CORVIDIA THERAPEUTICS SHAREHOLDERS COULD ULTIMATELY AMOUNT TO 2.1 BILLION US DOLLARS IN CASH UPON ACHIEVEMENT OF CERTAIN REGULATORY AND SALES MILESTONES BY NOVO NORDISK.NOVO NORDISK WILL FUND UPFRONT PAYMENT FROM FINANCIAL RESERVES AND ONGOING SHARE BUYBACK PROGRAMME WILL NOT BE IMPACTED.

Novo Nordisk Says Step 1 Trial Met Both Primary Endpoints

June 4 (Reuters) - Novo Nordisk A/S <NOVOb.CO>::REG- NOVO NORDISK REPORTS WEIGHT LOSS OF 14.9% (16.9% IF TAKEN AS INTENDED) IN STEP 1 TRIAL.STEP 1 TRIAL MET BOTH PRIMARY ENDPOINTS.

Novo Nordisk Says Semaglutide 2.4 Mg Demonstrates Superior, Sustained Weight Loss Versus Placebo & In Addition 17.4% Weight Loss After 68 Weeks In Step 4 Trial

May 13 (Reuters) - Novo Nordisk A/S <NOVOb.CO>::NOVO NORDISK - ANNOUNCED HEADLINE RESULTS FROM STEP 4, FIRST COMPLETED PHASE 3A TRIAL IN STEP PROGRAMME.NOVO NORDISK- SEMAGLUTIDE 2.4 MG DEMONSTRATES SUPERIOR, SUSTAINED WEIGHT LOSS VERSUS PLACEBO&IN ADDITION 17.4% WEIGHT LOSS AFTER 68 WEEKS IN STEP 4 TRIAL.

Novo Nordisk: Maziar Mike Doustdar Sells 12,000 Shares In Co

May 12 (Reuters) - Novo Nordisk A/S <NOVOb.CO>::MAZIAR MIKE DOUSTDAR SELLS 12,000 SHARES IN CO WITH PRICE DKK 430.91 PER SHARE.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up